Filter

1 - 10 of 532 Results

  • Health Affairs Blog: Medicare Premium Support Proposals Could Increase Costs for Today’s Seniors, Despite Assurances

    Perspective

    In a Health Affairs blog post, Tricia Neuman and Gretchen Jacobson of the Kaiser Family Foundation examine how proposals to convert Medicare to a premium support system could lead to higher Medicare premiums and cost-sharing for seniors currently enrolled in the program, even if today’s seniors are “grandfathered” and the new system is phased-in for people ages 55 and younger. The blog post explains how today’s seniors could face higher health care costs, if older beneficiaries are separated, at least actuarially, from younger ones. Lawmakers could implement policies to prevent cost increases for seniors, but doing so would reduce Medicare savings, a key objective of many premium support proposals.

  • The Gap in Medigap

    Perspective

    This policy insight examines the low rate of Medigap coverage among people under age 65 with disabilities on Medicare and the federal law that governs consumer rights and protections related to Medigap open enrollment.

  • Medicaid Home and Community-Based Services Enrollment and Spending

    Issue Brief

    Medicaid continues to be the primary payer for home and community-based services (HCBS) that help seniors and people with cognitive, physical, and mental health disabilities and chronic illnesses with self-care and household activities. This issue brief presents Medicaid HCBS enrollment and spending data from KFF's annual state survey and includes tables with detailed state-level data.

  • A Look at Recent Proposals to Control Drug Spending by Medicare and its Beneficiaries

    Issue Brief

    In response to higher drug spending growth and heightened attention to drug prices, policymakers have proposed a variety of policy initiatives to lower the cost of prescription drugs in Medicare. This brief examines in detail the range of proposals offered by the Trump Administration and members of Congress for lowering the cost of prescription drugs, their known effects on the federal budget, and their potential implications for beneficiaries and other stakeholders.